American Century Companies Inc. Trims Position in Organon & Co. $OGN

American Century Companies Inc. lessened its stake in Organon & Co. (NYSE:OGN) by 6.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 39,997 shares of the company’s stock after selling 2,951 shares during the quarter. American Century Companies Inc.’s holdings in Organon & Co. were worth $596,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Organon & Co. during the 1st quarter worth about $60,000. PARK CIRCLE Co grew its holdings in Organon & Co. by 640.7% during the 1st quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock worth $60,000 after acquiring an additional 3,460 shares in the last quarter. GAMMA Investing LLC grew its holdings in Organon & Co. by 186.9% during the 1st quarter. GAMMA Investing LLC now owns 4,611 shares of the company’s stock worth $69,000 after acquiring an additional 3,004 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in Organon & Co. during the 4th quarter worth about $111,000. Finally, SBI Securities Co. Ltd. grew its holdings in Organon & Co. by 17.6% during the 1st quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company’s stock worth $114,000 after acquiring an additional 1,145 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $10.37 on Friday. The firm has a market capitalization of $2.69 billion, a P/E ratio of 3.85, a PEG ratio of 0.88 and a beta of 0.60. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The company has a 50 day moving average price of $9.59 and a 200 day moving average price of $11.06. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $21.25.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.94 by $0.06. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. Organon & Co.’s revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Sell-side analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.8%. Organon & Co.’s dividend payout ratio (DPR) is currently 2.97%.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Piper Sandler dropped their target price on shares of Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, May 15th. BNP Paribas upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.